NCT00754975

JACTAX LD Drug Eluting Stent Trial

A Clinical Trial Comparing the Performance of the JACTAX LD DES With the TAXUS™ Libertè™ DES

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 130 (actual)
• Sponsor: Boston Scientific Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Prospective, multi-center, randomized trial. A maximum of 130 patients will be enrolled, in a 2:1 ratio to receive either the JACTAX LD stent or the TAXUS™ Libertè™ stent to evaluate the efficacy of the product.

Detailed description

The JACTAX Drug Eluting Stent has been designed to minimize the amount of polymer in contact with the vessel surface, thus potentially reducing the incidence of untoward side effects. The Juxtaposed Ablumenal Coating Process is capable of exclusive coating on the ablumenal side of pre-mounted bare metal stents. Juxtaposed Ablumenal Coating is a proprietary formulation containing a bioerodable polymer. The combination of the Juxtaposed Ablumenal Coating Process and Juxtaposed Ablumenal Coating create a unique microstructure surface, and reduces the amount of required polymer.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DEVICE	JACTAX LD DES	Drug Eluting Stent
DEVICE	TAXUS™ Libertè™ DES	Drug Eluting Stent

Timeline

• Start date: 2008-01-01
• Primary completion: 2009-05-01
• Completion: 2010-07-01
• First posted: 2008-09-18
• Last updated: 2017-03-01

Locations

5 sites across 1 country: Germany